BIOFRONTERA INC. WARRANTS
NASDAQ: BFRIW (Biofrontera Inc. Warrants)
Last update: 1 hour ago0.015
0.01 (53.06%)
| Previous Close | 0.010 |
| Volume | 116 |
| 52 Weeks Range |
| Profit Margin | -30.33% |
| Operating Margin (TTM) | -52.95% |
| Diluted EPS (TTM) | -1.30 |
| Quarterly Revenue Growth (YOY) | 8.50% |
| Total Debt/Equity (MRQ) | 1,036.89% |
| Current Ratio (MRQ) | 1.40 |
| Operating Cash Flow (TTM) | -11.06 M |
| Levered Free Cash Flow (TTM) | -6.28 M |
| Return on Assets (TTM) | -49.47% |
| Return on Equity (TTM) | -384.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Biofrontera Inc. Warrants | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | NA |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -0.50 |
|
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |